http://tomcarter.co.uk/archive/2014/ernesto-canovas-studio-documentation/?utm_source=rss Supergen enter (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is $147M. Revenue for Q1 was $14.4M primarily from go to link Dacogen royalties with a profit of $4.7M. Revenues are expected to be in the $41-$44M in 2010 and flat next year. The R&D pipeline in cancer therapeutics based upon epigenetic targets is being funded with $29M primarily from existing product royalties and a partnership with Glaxo (GSK). Three products are in the pipeline with the MP-470 TK inhibitor in Phase I.
The stock is owned by several blue chip institutional investors such as Orbimed,BVF Partners, Wellington and Blackrock.